Combinatorial Synthesis and Virtual Screening of Novel Oxazine and Thiazine Mini Libraries for Antidiabetic Activity

 

S.A. More*, N.M. Bhatia

Department of Pharmaceutical Chemistry, Bharati Vidyapeeth College of Pharmacy, Near Chitranagari, Kolhapur – 416013.

*Corresponding Author E-mail: moresuje51@gmail.com

 

ABSTRACT:

The purpose of the present work was to investigate, following previous works, oxazine and thiazine analogues as antihyperglycemic agent by carrying out docking studies. A series of substituted oxazine and thiazine has been synthesized combinatorially and intermediate compounds were confirmed from the results of chromatographic, spectral and physicochemical analysis. By comparing the interactions of the reference and synthesized molecules with selected target enzymes DPP-4 and glucokinase enzyme, it is clear that the compound can bind strongly with the receptor molecules which suggest that rationale used to optimize structural requirements of ligand with respect to selected targets was appropriate. Two molecules 4-(4-aminophenyl)-6-(2-chloroquinolin-3-yl)-N-pyridin-2-yl-6H-1,3-oxazin-2-amine (A6B3) and 4-(2,4-dimethyl-1H-pyrrol-3-yl)-6-(2,4-dimethoxyphenyl)-N-(pyridin-2-yl)-6H-1,3-oxazin-2-amine-2-carboxylate (A4B3) showed good antidiabetic activity.

                                                                            

KEYWORDS: Oxazine, thiazine, antidiabetic activity

 


INTRODUCTION:

Most pharmaceutical companies use combinatorial chemistry to create libraries of organic molecules for drug screening and lead optimization. It is a means of producing a large number of compounds in a short period of time, using a defined reaction route and a large variety of starting materials and reagents (1). Substituted oxazine and thiazine derivatives show different activities like antimalerial (2), antitubercular (3), antibacterial (4), anti-inflammatory (5), analgesic and ulcerogenic(6), lipid modulating and antidiabetic activity (7). Based on the above observation it is worthwhile to prepare newer compounds for their antidiabetic activity. In the view of the varied biological and pharmacological application, we synthesized some novel derivatives of oxazine and thiazine.

 

Diabetes is the leading disease which cannot be ignored at all and also the marketed antidiabetic drugs are showing resistance and adverse effect frequently. In the current status of therapy for diabetes glucose transporters and various biochemicals related to chronic diabetes mellitus attract attention and hence comprehensive study of antidiabetic activity of the identified leads along with other biochemical variables is desirable (8).

 

In the field of molecular modeling, docking is a method which predicts the preferred orientation of one molecule to a second when bound to each other to form a stable complex. Knowledge of the preferred orientation in turn may be used to predict the strength of association or binding affinity between two molecules using for example scoring functions (9).

 

DPP-4 inhibition prevents the inactivation of glucagon-like peptide 1 (GLP-1), which increases levels of active          GLP-1(10). While, activation of glucokinase enzyme promotes hepatic glucose uptake and pancreatic insulin secretion (11), therefore, these both are targets of interest for diabetic therapy in type II diabetes.

 

 


MATERIALS AND METHODS:

Materials:

Chemicals used: Benzaldehyde, 4-nitro benzaldehyde, furfural, urea, thiourea (Loba Chemie), 3, 4-dichloro acetophenone, 2, 4-dimethoxy acetophenone (SDFCL), 2-amino pyridine, acetanilide (HiMedia).

Instruments used: Magnetic stirrer (Biotechnique India), Autoanalyzer (Microlab 300)

Methods:                                                                                                                                                                                              

1. Scheme of synthesis:

1.1. Synthesis of diversely substituted chalcone derivatives.

a) Synthesis of 2,4-dimethyl,3-acetyl-5-carbethoxypyrrole (12)


 

2, 4-dimethyl, 3-acetyl-5- carbethoxypyrrole

 

Glacial acetic acid (1.2 liters) and ethyl acetoacetate (3.09 mol) were taken into a 3 liter three neck flask provided with a stirrer and surrounded by ice bath. To this solution was added a solution of sodium nitrite (3.55 mol) in 400 ml of water with constant stirring such that temperature does not rise above 120C. The mixture was stirred for further 2 hours and then at room temperature for 12 hours without disturbing and then added (3.48 mol) of acetyl acetone at one time. Now 450 gm of zinc dust was added slowly to the reaction mixture in portions of 10 gm. The rate of addition is regulated so that temperature does not rise above 600C. Further the reaction mixture was refluxed for 2 to 3 hours on a hot plate. The hot solution was poured through a fine copper sieve with stirring into 30 liter of ice water. The product was filtered, washed with water and recrystallized from ethanol into get the pure white crystals.

 

b) Synthesis of 2-chloroquinoline 3-aldehyde (13)

2-chloroquinoline 3-aldehyde                

 

Dimethylformamide (0.15 mol) was taken in a clean 100 ml round bottom flask, the temperature of which is maintained below -10 0C. Phosphoryl chloride (0.35 mol) was added drop wise to this solution with constant stirring. After complete addition the reaction mixture was stirred for few minutes. Acetanilide (0.05 mol) was added at once to the reaction mixture and stirred until dissolve. The reaction temperature was raised to 75 0C and maintained for 16 hours. The reaction mixture was poured into ice cold water (300 ml) and stirred for 0.5 hours. The precipitate solid was collected by filtration and washed with water, air dried and recrystallized from ethyl acetate to afford the product as faint yellow crystals. 

 

c)       Synthesis of Chalcone derivatives: (14)

To a solution of substituted acetophenone (0.01 mol) and substituted aldehyde (0.01 mol) in ethanol at room temperature was added sodium hydroxide (0.01 mol) with constant stirring. The reaction mixture was further stirred until a precipitate was formed. The reaction mixture was diluted with ice water and neutralized by using 0.01 N dilute hydrochloric acid solution. The product was filtered, washed with water and recrystallized from ethanol to get the respective chalcone derivatives.

 

Table No. 1- Different R and R’ substituents of chalcone derivatives

Compound Code

R

R’

A1

 

 

A2

 

 

A3

 

 

A4

 

 

A5

 

 

A6

 

 

 

1.2    Synthesis of pyridine urea and 5-bromo phenyl thiourea derivatives.

a)         Synthesis of pyridine urea derivative (15)                                                                                                                                                     B3

 

To a solution of ethanolic sodium ethoxide i. e. 0.05 g of sodium metal in absolute ethanol (50 ml) was added 2- amino pyridine (0.01 mol) and urea (0.01 mol). The mixture was heated under reflux for 4 hours then evaporated in vacuo. Resulting solid product was collected by filtration and recrystallized from ethanol.

 

b)       Synthesis of 4-bromo acetanilide (14)

 

13.5 g (0.1 mol) of finely powdered acetanilide was dissolved in 45 ml f glacial acetic acid in 350 ml conical flask. In another small flask 17 g (5.3 ml, 0.106 mol) of bromine was dissolved in 25 ml of glacial acetic acid, and transferred to separating funnel. The preparation had conducted in fume cupboard. Bromine solution was added slowly and with constant shaking to insure thorough mixing; flask was placed in cold water. When all the bromine had been added, the solution become an orange coloured due to the slight excess of bromine; part of reaction product was crystallized out. The final reaction mixture was kept at room temperature for 30 minutes with occasional shaking. The reaction product was poured into 400 ml of water, rinsed the flask with about 100 ml of water. The reaction mixture was stirred well. The crystalline precipitate was filtered, washed with cold water and recrystallised with dilute ethanol.

 

Synthesis of 4-bromo aniline (14)

 

18 g (0.084 mol) of p-bromoacetanilide dissolved in 35 ml of boiling ethanol contained in a 500 ml round bottomed flask equipped with a reflux condenser. With a aid of a pressure equalizing dropping funnel 22 ml of concentrated hydrochloric acid was added down the condensers in small portions to the boiling solution. The reaction mixture was refluxed for 30-40 min. or until a test portion remains clears when diluted with water. Diluted with 150 ml of water, and fitted the flask with a condenser set for downward distillation. The mixture was distilled from an air bath. Approximately 100 ml of distillate was collected; the latter consists of ethyl acetate, ethanol and water. The residual solution of p-bromoaniline hydrochloride was poured into 100 ml of ice water, and with vigorous stirring 5% sodium hydroxide solution was added until just alkaline. The p-bromoaniline was separated as oil, which soon crystallizes. Recrystallised by dilute ethanol. The crystals were filtered, washed with cold water.

 

c)       Synthesis of 4-bromo phenyl thiourea derivative (16)

          p-bromoaniline        Thiourea                                                                   B4

 

 

In flask placed 200 g (1.5 mol) of 24 per cent aqueous 4-bromo aniline solution and concentrated hydrochloric acid was added until acidic to methyl red; about 155 cc required. Water was added to bring total weight 500 g, 300 g (5 mol) of thiourea was added and solution was boiled gently under reflux for 2-3 hour. The solution was cooled to room temperature, 100g (1.5 mol) of 95 % sodium nitrite was dissolved in it and whole cooled to 0 0C. The crystals were stirred to a paste with about 50 cc of cold water, sucked as dry as possible and dried in vacuum desiccator to constant weight.

 

Identification of synthesized compounds:

Table No. 2- IR interpretation of synthesized intermediate compounds

Sr. No.

Compound code

IR cm-1

1

A1

1665.29cm-1(C=O str), 1592.62cm-1 (CH=CH), 3061.44cm-1 (CH str), 789cm-1 (Ar-Cl)

2

A2

1658.48 cm-1 (C=O str), 1598.7 cm-1 (CH=CH), 1516.74 cm-1 (Ar-NO2)

3

A3

1665.23cm-1 (C=O), 1588.09 cm-1 (CH=CH), 723.09 cm-1 (Ar-Cl), 1015.34cm-1 (C=O str)

4

A4

1520.02 cm-1 ( CH=CH), 1678.73 cm-1 (C=O str), 3283.21 cm-1 (NH), 1266.04 cm-1 (ester)

5

A5

1685.48 cm-1 (C=O str), 1577.49 cm-1 (CH=CH), 3283.21 cm-1 (NH), 1045.23 cm-1(Ar-Cl)

6

A6

1586.16 cm-1 (C=O str), 1651.73 cm-1 (CH=CH), 756.92 cm-1 (Ar-Cl), 3335.28 cm-1 (NH), 835.99 cm-1 (P-distribution)

7

B3

3199.33cm-1 (NH), 1618.95cm-1 (C=O str), 3292.16cm-1 (N – pyridine)

8

B4

503.33 cm-1 (Ar-Br), 3189.68 cm-1 (NH), 744.38 cm-1 (C-S), 1394.28 cm-1 (C-N str)

 

1.3    Synthesis of oxazine and thiazine mini libraries (17)

a)       Oxazine derivatives:

 

Table No. 3- Different R and R’ substituents of oxazine derivatives

Sr No.

Compound code

R

R’

R’’

1

A1B1

 

 

H

2

A2B1

 

 

H

3

A3B1

 

  

H

4

A4B1

 

 

H

5

A5B1

 

 

H

6

A6B1

 

 

H

7

A1B3

 

 

 

8

A2B3

 

 

 

9

A3B3

 

  

 

10

A4B3

 

 

 

11

A5B3

 

 

 

12

A6B3

 

 

 

 

b)       Thiazine derivatives:

 

Table No. 4 - Different R and R’ substituents of thiazine derivatives

Sr No.

Compound code

R

R’

R’’

1

A1B2

 

 

H

2

A2B2

 

 

H

3

A3B2

 

  

H

4

A4B2

 

 

H

5

A5B2

 

 

H

6

A6B2

 

 

H

7

A1B4

 

 

 

8

A2B4

 

 

 

9

A3B4

 

  

 

10

A4B4

 

 

 

11

A5B4

 

 

 

12

A6B4

 

 

 

 

A mixture of 6 different chalcones (0.002mol), thiourea/urea (0.002 mol) were dissolved in ethanolic sodium hydroxide (10ml) was stirred about 2-3 hours with a magnetic stirrer. This was then poured into 400 ml of cold water with continuous stirring for an hour and then kept in refrigerator for 24 hours. The precipitate obtained was filtered, washed and recrystallized. The completion of the reaction was monitored by TLC.

 

2. Docking study:

2.1. Target protein active site modelling

The 3-D coordinates in the X-ray crystal structure of PDBs complexed with inhibitors, were selected as the receptor model in the virtual screening with docking simulations. After removing the ligand and solvent molecules, hydrogen atoms were added to each protein atom. Then the active sites of receptors were analyzed. The compounds in the docking library were selected with the drug-like filters that select only the compounds with physicochemical properties of potential drug candidates and without reactive functional group(s).

 

Fig. No. 2 - Active site amino acids of DPP-4 enzyme (PDB ID-2G63)

 

Fig. No. 3 - Active site amino acids of Glucokinase enzyme (PDB ID-3H1V)

3.2. Docking of synthesized oxazine and thiazine analogues with dpp-4 and glucokinase enzymes

Ligands were designed on Vlife Molecular Design Suite 3.5 by using Biopredicta. All the molecular modeling studies were performed on pentim core2duo workstation using Sybyl.  Geometries were optimized by energy minimization using MMFF94 forcefield and Gasteiger-Marsili charges for the atoms, till gradient of 0.001kcal/mol/A0 was reached.

Screening of designed molecules was performed with different antidiabetic targets.

 

After performing Batch GRIP docking the results found are as follows-

Table No. 6 - Docking scores of all synthesized molecules with DPP-4 and glucokinase enzymes

Sr No.

Compound code

DPP-4 binding Energy

(Kcal/mol)

(PDB ID- 2G63)

Glucokinase binding Energy

(Kcal/mol)

(PDB ID- 3H1V)

1

A1B1

-50.56

-51.90

2

A2B1

-47.70

-28.45

3

A3B1

-50.53

-45.48

4

A4B1

-46.06

-29.35

5

A5B1

-45.72

-35.20

6

A6B1

-51.90

-55.21

7

A1B2

-47.37

-63.18

8

A2B2

-51.74

-45.04

9

A3B2

-46.50

-52.73

10

A4B2

-52.20

-26.99

11

A5B2

-59.73

-9.41

12

A6B2

-50.52

-46.10

13

A1B3

-55.51

-45.13

14

A2B3

-59.70

-37.48

15

A3B3

-56.88

-50.04

16

A4B3

-56.91

-63.19

17

A5B3

-77.68

-15.36

18

A6B3

-64.12

-68.79

19

A1B4

-50.09

-21.77

20

A2B4

-57.19

-45.00

21

A3B4

-61.59

-53.47

22

A4B4

-48.47

-5.42

23

A5B4

-48.24

-20.33

24

A6B4

-50.27

-54.28

25

Reference

Ligand

-57.14

-135.69

 

Fig. No. 4 – Interaction of reference ligand (blue) with amino acids in the active site of DPP-4 enzyme

Reference ligand showed hydrogenbond interaction (ARG125B, GLU205B, TYR547B), hydrophobic interaction (SER552B, LYS554B, SER630B, TYR631B, VAL656B), VDW interaction (ARG125B, TYR547B, LYS554B, SER630B, TYR666B)

 

Fig. No. 5 - Interaction of virtually and biologically active molecule A6B3 (orange) with amino acids in the active site of DPP-4 enzyme

A6B3 showed PI stacking interaction (PHE357B, TYR547B, TRP629B), VDW interaction (ARG125B, GLU205B, PHE357B, TYR547B, LYS554B, GLN553B, TRP629B)

 

Fig. No. 6 - Interaction of biologically active molecule A4B3 (green) with amino acids in the active site of DPP-4 enzyme

A4B3 showed hydrogenbond interaction (TRP629B), hydrophobic interaction (TYR547B, SER552B, TRP629B, GLY741B), PI stacking interaction (TYR547B, HIS740B, TRP627B), VDW interaction (VAL546B, TYR547B, LYS554B, TRP627B, CYS551B, TRP629B)

 

Fig. No. 7 – Orientation of reference ligand (blue) and virtually most active and biologically active molecules A5B3 (orange) and A6B3 (green) respectively in the active site of DPP-4 enzyme

 

Fig. No. 8 – Interaction of reference ligand (blue) with amino acids in the active site of Glucokinase enzyme

Reference ligand showed hydrogenbond interaction (ARG63X), hydrophobic interaction (VAL62X, ARG63X, GLY97X, ILE159X), VDW interaction (VAL62X, TYR61X, ARG63X, SER64X, THR65X, GLN98X, GLY97X)

 

Fig. No. 9 - Interaction of virtually and biologically active molecule A6B3 (orange) with amino acids in the active site of Glucokinase enzyme

A6B3 showed hydrophobic interaction (THR65X, PRO66X), PI stacking interaction (TYR214X), VDW interaction (VAL62X, ARG63X, SER64X, THR65X, PRO66X, GLN98X, ILE211X, TYR214X, MET235X)

 

Fig. No. 10 - Interaction of biologically active molecule A4B3 (green) with amino acids in the active site of Glucokinase enzyme

A4B3 showed hydrogenbond interaction (TYR215X), hydrophobic interaction (ILE211X, SER212X, CYS213X, TYR214X, LEU451X), PI stacking interaction (TYR214X), VDW interaction (VAL62X, ARG63X, SER64X, PRO66X, GLN98X, GLU67X, MET210X, ILE211X, CYS213X)

 

Fig. No. 11 – Orientation of reference ligand (blue) and virtually most active and biologically active molecules A6B3 (orange) and A4B3 (green) respectively in the active site of Glucokinase enzyme

 

3.1 Synthesis of lead molecule:

After finding the lead molecule they were synthesized individually. The general procedure for synthesizing the lead molecules as follow-

A mixture of substituted chalcone (0.002mol), pyridine urea (0.002 mol) were dissolved in ethanolic sodium hydroxide (10ml) was stirred about 2-3 hours with a magnetic stirrer. This was then poured into 400 ml of cold water with continuous stirring for an hour and then kept in refrigerator for 24 hours. The precipitate obtained was filtered, washed and recrystallized. The completion of the reaction was monitored by TLC.

 

IR interpretation of lead molecules:

Table No. 8- IR interpretation of synthesized lead molecules

Comp. No.

IR characteristics cm-1

A6B3

3342.03 cm-1 (NH), 732.10 cm-1(Ar-Cl), 3212.83 cm-1 (Aromatic C-H),   1580.38 cm-1 (C=N), 3212.83 cm-1 (N-pyridine)

A4B3

1643.05 cm-1 (C=O str), 3304.43 cm-1 (NH), 2987.27 cm-1 (Ar-CH str), 1513.85 cm-1 (CH=CH), 1140.69 cm-1 (C-O str), 1229.54 cm-1 (C-N str), 1437.67 cm-1 (Ar-OCH3).

NMR Interpretation of compound A6B3

 

Table No. 9- NMR Interpretation of compound A6B3

Lead code

δ PPM (CdCl3)

A6B3

 

7.449-8.130 (m, 5H-Aromatic), 3.337 (s, Aromatic-NH2), 3.873 (s, Aromatic-NH-Aromatic), 6.676-6.849 (t, 4H-Aromatic), 7.082-7.271 (t, 4H- Aromatic).

 

 


RESULT AND DISCUSSION:

All oxazine and thiazine derivatives were synthesized by condensation cum cyclization reaction of various substituted chalcones and urea and thiourea derivatives. Four and six compounds in each subset of the mini-library were confirmed by four and six spots in TLC. Intermediate compounds were confirmed from the results of chromatographic, spectral and physicochemical analysis. The synthesized lead molecules which contains terminal aromatic region attached to oxazine ring showed good interactions, because the presence of terminal aromatic region there are a lot of options of substitutions which leads to favorable bonding and stable ligand-amino acid residue interaction.

 

Compounds 4-(4-aminophenyl)-6-(2-chloroquinolin-3-yl)-N-pyridin-2-yl-6H-1,3-oxazin-2-amine (A6B3) and 4-(2,4-dimethyl-1H-pyrrol-3-yl)-6-(2,4-dimethoxyphenyl)-N-(pyridin-2-yl)-6H-1,3-oxazin-2-amine-2-carboxylate (A4B3) were having good antidiabetic activity by comparing binding energy with that of reference ligand.

 

CONCLUSION:

Pharmacophore model of leads showing various interaction sites such as hydrogen bond acceptor, hydrogen bond donor, van-der-walls area and hydrophobic surfaces which can be further optimized for better interaction. Docking study of leads reveals that for antidiabetic activity di substituted aromatic nitro groups, substituted pyridine and thiadiazole nucleus bridged by amide linkage were essential. There were a good correlation between virtual screening and observed biological activities of lead molecules which suggest that rationale used to optimize structural requirements of ligand with respect to selected targets was appropriate.

 

REFERENCES:

1.        Patrick GL. An Introduction to Medicinal Chemistry. 3rd ed. 2005: 299-324.

2.        Vennerstrom JL, Makler MT, Angerhofer CK and Williams JA. Antimalarial Dyes Revisited: Xanthenes, Azines, Oxazines, and Thiazines, Antimicrobial Agents and Chemotherapy. Dec. 1995: 2671–2677.

3.        Agrawal YK, Bhatt HG, Raval HG, Oza PM. Emerging trends in tuberculosis therapy, Journal of Scientific and Industrial Research, Vol 66, March 2007: 191-208.

4.        Dabholkar VV, Patil SR, Pandey RV. Synthesis and antimicrobial activity of some novel heterocycles containing thiazole, oxazole, thiazine, oxazine and triazole moiety, J. Iran. Chem. Res., 4, 2011: 33-38.

5.        Pearce AN, Chia EW, Berridge MV, Clark GR. Anti-inflammatory Thiazine Alkaloids Isolated from the New Zealand Ascidian Aplidium sp.: Inhibitors of the Neutrophil Respiratory Burst in a Model of Gouty Arthritis, Journal of Natural Products, 2007, Vol. 70, No. 6: 936-940.

6.        Dabholkar VV, Parab SD. Synthesis of chalcones, 1, 3-thiazines and 1, 3-pyrimidines derivatives and their biological evaluation for anti-inflammatory, analgesic and ulcerogenic activity, The Pharma Research (T. Ph. Res.), 2011, 5(1): 127-143.

7.        Das SK, Reddy KA, Abbineni C, Iqbal J. Novel Thieno Oxazine Analogues as Antihyperglycemic and Lipid Modulating Agents, Bioorganic and Medicinal Chemistry Letters 13, 2003: 399–403.

8.        Al-Zubairi AS, Eid EM. Molecular Targets in the Development of Antidiabetic Drugs, International Journal of Pharmacology, 6, 6, 2010: 784-795.

9.        Bachwani M, Kumar R. Molecular Dockig: A Review, IJRAP, 2011, 2 (6): 1746-1751.

10.     Gallwitz B. Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapy, Touch Briefings 2008: 40-43.

11.     Boyd SA, Aicher TD, Anderson D. ARRY-403, A Novel Glucokinase Activator with Potent Glucose-Dependent Anti-Hyperglycemic Activity in Animal Models of Type 2 Diabetes Mellitus, Array BioPharma Inc., Boulder, CO 80301, Symposium: Type 2 Diabetes and Insulin Resistance (J3), Jan 20-25, 2009, Banff, AB

12.     Li JJ, In; Name Reactions in Heterocyclic Chemistry, Wiley Intersciences, New York, 2002: 179.

13.     Horning, EC, In., Organic Chemistry, Vol-III, John Wiley and Sons, New York, 1995: 513.

14.     Furniss BS, Hannaford AJ, Smith PWG, Tatchell AR, Vogel’s Textbook of Practical Organic Chemistry, 5th ed., 1989.

15.     Gilman H and Blatt AH, Organic Synthesis, Collective Volume I, 2nd ed., 1941: 453.

16.     Mann FG, Sounders BS, Practical Organic Chemistry, 4th ed., 1960: 108.

17.     Kalirajan R, Sivakumar SU, Jubie S, Gowramma B, Suresh B. Synthesis and biological evaluation of some heterocyclic derivatives of Chalcones, International Journal of ChemTech Research, Jan – March 2009, Vol.1, No.1: 27-34.


 

 

 

Received on 25.06.2014         Modified on 20.07.2014

Accepted on 10.08.2014         © AJRC All right reserved

Asian J. Research Chem. 7(8): August 2014; Page 751-764